Predilife S.A. (ALPRE.PA)
Paris · EUR · Healthcare · Diagnostics & Research
€0.92 (-8.91%) as of
Key statistics
- Market cap
- 3.63M
- EPS (TTM)
- -1.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.8500 – 4.0000
- Beta
- 0.28
- Revenue (TTM)
- 835.81k
- Profit margin
- 0.00%
- Volume
- 134.00
About Predilife S.A.
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Villejuif, France
- Employees
- 20
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.